Skip to content

Maternal OXygen Immediately before birth: The MOXIE feasibility study

Maternal OXygen Immediately before birth: The MOXIE feasibility study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12623001037695
Acronym
MOXIE feasibility
Enrollment
19
Registered
2023-09-26
Start date
2024-10-09
Completion date
2025-10-09
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

We aim to determine if maternal oxygen supplementation 5-10 min prior to birth of term and near-term infants (32 weeks gestation or above at birth) utilising heated humidified high flow nasal cannula with 100% oxygen at 30-70L/min is feasible at both caesarean section and vaginal births. The information gained from this feasibility study will inform the planned randomised controlled trial of maternal oxygen in very preterm infants.

Interventions

Maternal oxygen supplementation via heated humidified high flow nasal cannula for 5-10 minutes at 100% oxygen at 30-70L/min before umbilical cord is clamped. Adherence will be monitored in person by one of two principal investigators and will be documented in study database

Sponsors

Douglas Blank
Lead SponsorIndividual

Study design

Allocation
Non-randomised trial
Primary purpose
Prevention

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

Expecting women between 32 weeks and 0 days to 41 weeks and 6 days gestational age giving birth

Exclusion criteria

History of severe maternal epistaxis History of major nasal/sinus surgery or pathology Concurrent maternal chronic obstructive pulmonary disease (COPD) exacerbation Fetus with congenital abnormality that would alter the expected SpO2 targets in the minutes after birth; ie antenatal diagnosis of ductal dependant cardiac lesions, congenital diaphragmatic hernia, etc. Monochorionic twins with evidence of twin-to-twin transfusion syndrome or multiples of more than 2.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026